Company Analysis
Sign in

Jyong Biotech Ltd. (MENS)

Nasdaq: MENS · Pharmaceutical Preparations · New Taipei City, TW · filing with the SEC since 2023
Full chart Alerts Compare
Grade4.7
◀ Past 6.3● Present 4.6▶ Future 3.8
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$4.7M-54.7%
Earnings per share$-0.06-50.0%
Operating cash flow-$3.0M+16.1%
Cash$1.2M+1066.3%
Debt$2.1M
Shareholders’ equity-$24.9M+31.8%
Shares, diluted73.0M+2.0%
Return on equityn/a
The recordfrom its filings
Filings in 202612
Newest filingMay 15 · 20-F
Annual reportMay 15, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted4
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Apr 24, 2026 · SEC EDGAR · Form SCHEDULE 13D
Activist holder notice
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton MENS · research, not advice